Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $18.3333.

EPRX has been the topic of several analyst reports. Stifel Nicolaus initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They set a “buy” rating and a $25.00 target price on the stock. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th.

Institutional Trading of Eupraxia Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new stake in Eupraxia Pharmaceuticals in the first quarter valued at about $5,137,000. DV Trading LLC acquired a new stake in Eupraxia Pharmaceuticals in the first quarter valued at about $1,998,000. Bank of America Corp DE boosted its stake in Eupraxia Pharmaceuticals by 5.9% in the first quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock valued at $1,942,000 after buying an additional 14,900 shares in the last quarter. Ally Bridge Group NY LLC boosted its stake in Eupraxia Pharmaceuticals by 66.0% in the first quarter. Ally Bridge Group NY LLC now owns 660,375 shares of the company’s stock valued at $4,781,000 after buying an additional 262,480 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Eupraxia Pharmaceuticals by 33.2% during the first quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock valued at $1,893,000 after purchasing an additional 65,099 shares in the last quarter.

Eupraxia Pharmaceuticals Stock Performance

EPRX opened at $6.04 on Friday. The firm has a market cap of $392.72 million, a P/E ratio of -5.75 and a beta of 0.97. Eupraxia Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $9.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The business’s fifty day moving average is $6.97 and its 200-day moving average is $7.37.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.86 EPS for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.